Previous close | 87.70 |
Open | 87.68 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 87.63 - 92.11 |
52-week range | 80.60 - 104.90 |
Volume | |
Avg. volume | 1,365,420 |
Market cap | 116.342B |
Beta (5Y monthly) | 0.45 |
PE ratio (TTM) | 21.40 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.76 (4.29%) |
Ex-dividend date | 13 May 2024 |
1y target est | N/A |
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.
Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.
(Reuters) -Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.